Clinical Trial: NRG CCTG MA.39

NRG CCTG MA.39

Status: Open

NCT#03488693

Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer

Eligible for screening study DCP 001

For CCTG MA.39, please credit NRG all accruals.

CCTG MA.39-Optional Questionnaire Component is closed to accrual effective August 2, 2022

The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho and Wyoming through National Cancer Institute (NCI) sponsored clinical research.

Available Clinical Trials

Clinical Trial: NRG CCTG MA.39

NRG CCTG MA.39

NCT#03488693

Navigation

About Us

Contact Us